Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity

• DOI: 10.1016/j.ejpb.2023.08.014
• Publication Date: 2023-08-25T09:15:09Z
• Authors: Thomas Vazquez; Léa Torrieri-Damard; Fabien Pitoiset; Béatrice Levacher; James Vigneron; Luzia Mayr; Faustine Brimaud; Benjamin Bonnet; Christiane Moog; David Klatzmann; Bertrand Bellier
• Keywords: HIV vaccine; HIV Antigens

Mucosal surfaces serve as the primary entry points for pathogens such SARS- CoV-2 coronavirus or HIV in human body. vaccination plays a crucial role to successfully induce long-lasting systemic and local immune responses confer sterilizing immunity. However, antigen formulations delivery methods must be properly selected since they are decisive quality magnitude of elicited mucosa. We investigated significance using particulate forms mucosal by comparing VLP- protein- based vaccines mouse model. Based on prime-boost immunization protocol combining (i) HIV- pseudotyped recombinant VLPs (HIV-VLPs) (ii) plasmid DNA encoding (pVLPs), we demonstrated that combination intranasal primes intravaginal boosts is optimal elicit both humoral cellular memory Interestingly, our results show contrast proteins, antigens high-quality characterized high breadth, long-term neutralizing activity cross-clade reactivity, accompanying with T follicular helper cell (TFH) response. These underscore potential VLP-based vaccine effectively instigating long-lasting, HIV-specific immunity point out specific form driving responses.